FDA Issues Emergency Use Authorization for Generic Over-the-Counter Drug to Treat New World Screwworm in Dogs and Cats
FDA issued an Emergency Use Authorization (EUA) for generic Nitenpyram (over-the-counter) to treat New World screwworm in dogs and cats, allowing immediate use without full NDA/ANDA approval.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 27, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B) facilities should confirm how it applies to their specific situation before acting. There is a time constraint attached: Immediately; EUA is effective upon issuance and remains until revoked.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
FDA now permits distribution and use of generic Nitenpyram tablets without an approved ANDA, under EUA terms.
Who it affects
Generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B) facilities
What you must do
Manufacturers must ensure product meets EUA specifications (cGMP, labeling, stability) and report adverse events; compounding pharmacies may need to adjust formulations.
Deadline
Immediately; EUA is effective upon issuance and remains until revoked.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- Continuing the Suspension of Duty-Free De Minimis Treatment for All Countries
- FDA Issues Draft Guidance to Cut Unnecessary Animal Testing for Cancer Drugs
- FDA Issues Draft Guidance to Help Accelerate Cell and Gene Therapies for Patients
- FDA Expands Sunscreen Options for the First Time in 20 Years
- FDA Broadens Access to Over-the-Counter Naloxone Nasal Spray for Opioid Overdose